首页工具

搜索结果

Search Results for " icec0942 "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T10898	Samuraciclib hydrochloride ICEC0942 hydrochloride,CT7001 hydrochloride	Apoptosis; CDK	Apoptosis; Cell Cycle/Checkpoint
	Samuraciclib hydrochloride (ICEC0942 hydrochloride) 是一种具有选择性，ATP 竞争性和口服活性的CDK7抑制剂，IC50为 41 nM。它以 GI50值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生长，具有抗肿瘤作用。
T63650	Samuraciclib hydrochloride hydrate
	Samuraciclib (CT7001) hydrochloride hydrate 是有效的、选择性、ATP 竞争性的、口服具有活力的 CDK7 抑制剂 (IC50: 41 nM)。Samuraciclib hydrochloride hydrate 对 CDK7的选择性分别是 CDK1，CDK2 (IC50为 578 nM)，CDK5 和 CDK9 的 45 倍，15 倍，230 倍和 30 倍。Samuraciclib hydrochloride hydrate 能够抑制乳腺癌细胞系的生长 (GI50: 0.2-0.3 μM)，表现出有效的抗肿瘤效果。
T35650	Samuraciclib trihydrochloride
	Samuraciclib (CT7001) trihydrochloride is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib trihydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib trihydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib trihydrochloride has anti-tumor effects[1][2].
T61835	Samuraciclib
	Samuraciclib (CT7001) is a potent, selective, and orally active inhibitor of CDK7, with an ATP-competitive nature. It effectively inhibits CDK7 with an IC 50 value of 41 nM. Furthermore, Samuraciclib demonstrates remarkable selectivity ratios, with 45-fold, 15-fold, 230-fold, and 30-fold selectivity over CDK1, CDK2 (IC 50 of 578 nM), CDK5, and CDK9, respectively. Notably, Samuraciclib has been found to inhibit the growth of breast cancer cell lines, exhibiting GI 50 values ranging between 0.2-0....